

## Date: May 11, 2022

То,	То,
The Manager, Listing Department,	The Department of Corporate Service,
National Stock Exchange of India Limited (NSE),	BSE Limited,
Exchange Plaza, C – 1, Block – G, Bandra – Kurla	1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building,
Complex, Bandra (E), Mumbai-400 051.	Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - 400 001.
Scrip Code-LINCOLN	Scrip Code-531633

Dear Sir / Madam,

## Sub.: Intimation of Board Meeting.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Meeting of the Board of Directors of the Company is scheduled to be held on **Thursday, May 19**, **2022** at the Registered Office of the Company inter-alia to consider and approve the audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2022 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any.

Further, in continuation to our disclosure on closure of trading window dated March 31, 2022, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2022 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEU CALS LTD

**NIREN A. DESAI COMPANY SECRETARY &** 

## **COMPLIANCE OFFICER**

**Regd. Office :** "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380 060, Gujarat, India. **Phone :** +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288 **E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com



